Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in pulmonary arterial hypertension after prior endothelin receptor antagonist discontinuation due to liver enzyme abnormalities
2005-001564-31Phase 2Completed
- Sponsor
- Myogen
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Myogen. Started Jul 2005; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-001564-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001564-31.